d-alpha tocopherol has been researched along with ramipril in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (15.38) | 18.2507 |
| 2000's | 19 (73.08) | 29.6817 |
| 2010's | 2 (7.69) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Doris, CI; Dzavik, V; Hutchison, K; Lonn, EM; Pogue, J; Riley, WA; Sabine, MJ; Taylor, W; Tucker, J; Yusuf, S | 1 |
| Bosch, J; Gerstein, HC; Pogue, J; Taylor, DW; Yusuf, S; Zinman, B | 1 |
| Mann, JF | 1 |
| Scheen, AJ | 1 |
| Flynn, T; Stevermer, JJ | 1 |
| Hoogwerf, BJ; Young, JB | 1 |
| Yusuf, S | 1 |
| Bosch, J; Doris, C; Dzavik, V; Lonn, E; Moore-Cox, A; Riley, W; Smith, S; Teo, K; Yi, Q; Yusuf, S | 1 |
| Madsen, S; Reikvam, A | 1 |
| Mancini, GB; Stewart, DJ | 1 |
| Lonn, E | 1 |
| Iuliano, L; Micheletta, F; Spagnoli, LG; Violi, F | 1 |
| Bosch, J; Dagenais, G; Mitchell, LB; Pogue, J; Teo, KK; Yusuf, S | 1 |
| Dagenais, GR; Lonn, E; Ostergren, J; Sleight, P; Yi, Q; Yusuf, S | 1 |
| Dagenais, GR; Gerstein, HC; Lonn, E; Mann, JF; McQueen, M; Pogue, J; Yusuf, S | 1 |
| Bosch, J; Gerstein, HC; Lonn, E; McQueen, MJ; Yusuf, S | 1 |
| Balion, C; Bickel, C; Blankenberg, S; Cambien, F; Gerstein, H; Lonn, E; McQueen, MJ; Münzel, T; Pogue, J; Rupprecht, HJ; Smieja, M; Tiret, L; Yusuf, S | 1 |
| Al-Merri, K; Al-Nemer, K; Dagenais, G; Healey, J; Lonn, E; Mann, JF; Mathew, J; Salehian, O; Sumner, G; Yi, Q | 1 |
| Ajibade, TO; Ajileye, IW; Bolaji-Alabi, FB; Omobowale, TO; Oyagbemi, AA | 1 |
3 review(s) available for d-alpha tocopherol and ramipril
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Should the results of the HOPE study affect nephrological practice? For the HOPE investigators.
Topics: Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Drug Therapy, Combination; Hemodynamics; Humans; Kidney Diseases; Kidney Function Tests; Ramipril; Randomized Controlled Trials as Topic; Risk Factors; Vitamin E | 2000 |
[How should ACE inhibitors be used in myocardial infarction?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Follow-Up Studies; Humans; Myocardial Infarction; Ramipril; Randomized Controlled Trials as Topic; Risk Factors; Vitamin E | 2000 |
14 trial(s) available for d-alpha tocopherol and ramipril
| Article | Year |
|---|---|
The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators.
Topics: Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; Patient Selection; Ramipril; Research Design; Risk Factors; Vitamin E | 1996 |
Study design and baseline characteristics of the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E: SECURE.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Arteriosclerosis; Carotid Artery Diseases; Coronary Artery Disease; Disease Progression; Double-Blind Method; Female; Humans; Intracranial Arteriosclerosis; Male; Ramipril; Research Design; Risk Factors; Ultrasonography; Vitamin E | 1996 |
Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes Preven
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Factor Analysis, Statistical; Humans; Middle Aged; Placebos; Ramipril; Research Design; Risk Factors; Time Factors; Vitamin E | 1996 |
The HOPE study. Ramipril lowered cardiovascular risk, but vitamin E did not.
Topics: Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Diabetes Complications; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Ramipril; Risk Factors; Treatment Outcome; Vitamin E | 2000 |
[ACE inhibitor even prevents diabetes. Sensational HOPE Study].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Myocardial Infarction; Ramipril; Stroke; Vitamin E | 1999 |
Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE).
Topics: Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Arteriosclerosis; Blood Pressure; Carotid Artery Diseases; Creatinine; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Patient Compliance; Potassium; Prospective Studies; Ramipril; Risk Factors; Treatment Outcome; Ultrasonography; Vitamin E | 2001 |
Why were the results of the Heart Outcomes Prevention Evaluation (HOPE) trial so astounding?
Topics: Angiotensin-Converting Enzyme Inhibitors; Death; Diabetes Complications; Diabetic Angiopathies; Female; Heart Diseases; Humans; Male; Middle Aged; Ramipril; Vitamin E | 2001 |
Modifying the natural history of atherosclerosis: the SECURE trial.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Arteriosclerosis; Carotid Arteries; Drug Therapy, Combination; Humans; Middle Aged; Ramipril; Treatment Outcome; Ultrasonography; Vitamin E | 2001 |
Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Double-Blind Method; Female; Follow-Up Studies; Heart Arrest; Humans; Life Tables; Male; Middle Aged; Neurotransmitter Agents; Ramipril; Risk; Survival Analysis; Treatment Outcome; Vitamin E | 2004 |
Impact of cigarette smoking in high-risk patients participating in a clinical trial. A substudy from the Heart Outcomes Prevention Evaluation (HOPE) trial.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antioxidants; Cardiovascular Diseases; Female; Humans; Incidence; Male; Middle Aged; Morbidity; Myocardial Infarction; Preventive Medicine; Ramipril; Risk Factors; Smoking; Stroke; Treatment Outcome; Vitamin E | 2005 |
The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus; Diabetic Angiopathies; Fasting; Female; Glycated Hemoglobin; Humans; Kidney Diseases; Male; Placebos; Ramipril; Reference Values; Risk Factors; Vitamin E | 2005 |
The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cost-Benefit Analysis; Diabetes Complications; Female; Heart Failure; Humans; Inflammation; Kidney Diseases; Male; Myocardial Infarction; Natriuretic Peptide, Brain; Peptide Fragments; Prospective Studies; Ramipril; Stroke; Ventricular Function, Left; Vitamin E | 2005 |
Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; C-Reactive Protein; Coronary Artery Disease; Female; Fibrinogen; Heart Diseases; Humans; Interleukin-6; Male; Middle Aged; Myocardial Infarction; Natriuretic Peptide, Brain; Predictive Value of Tests; Ramipril; Risk Factors; Vitamin E | 2006 |
The prognostic significance of bundle branch block in high-risk chronic stable vascular disease patients: a report from the HOPE trial.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Bundle-Branch Block; Cardiovascular Diseases; Chronic Disease; Death, Sudden; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Europe; Female; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; North America; Proportional Hazards Models; Prospective Studies; Ramipril; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome; Vascular Diseases; Vitamin E | 2009 |
9 other study(ies) available for d-alpha tocopherol and ramipril
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
[Clinical study of the month. The HOPE study, a two-by-two factorial clinical trial with contrasted results].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Diabetes Complications; Humans; Middle Aged; Ramipril; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome; Vitamin E | 2000 |
Vitamin E does not prevent cardiovascular events in high-risk patients.
Topics: Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Dietary Supplements; Humans; Middle Aged; Multicenter Studies as Topic; Ramipril; Randomized Controlled Trials as Topic; Vitamin E | 2000 |
Clinical, public health, and research implications of the Heart Outcomes Prevention Evaluation (HOPE) Study.
Topics: Cardiovascular Diseases; Evaluation Studies as Topic; Humans; Public Health; Ramipril; Research; Treatment Outcome; Vitamin E | 2001 |
ACE inhibitor inhibits atherosclerosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Arteriosclerosis; Carotid Arteries; Carotid Artery Diseases; Humans; Ramipril; Ultrasonography; Vitamin E | 2001 |
[Ramipril can do more. Halting progression of atherosclerosis].
Topics: Angiotensin-Converting Enzyme Inhibitors; Arteriosclerosis; Carotid Stenosis; Disease Progression; Humans; Ramipril; Randomized Controlled Trials as Topic; Vitamin E | 2001 |
An ACE inhibitor to coronary patients: ramipril reduces mortality according to HOPE trial.
Topics: Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Coronary Disease; Humans; Ramipril; Treatment Outcome; Vitamin E | 2001 |
Effect of ramipril and vitamin E on atherosclerosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antioxidants; Carotid Artery Diseases; Disease Progression; Humans; Lipoproteins, LDL; Ramipril; Ultrasonography; Vitamin E | 2002 |
Supplementation of antihypertensive drug regimen with vitamin E ameliorates alterations of primary haemodynamic parameters and total antioxidant capacity in ovariectomised rats.
Topics: Animals; Antihypertensive Agents; Antioxidants; Dietary Supplements; Female; Hemodynamics; Hydrogen Peroxide; Oxidative Stress; Ramipril; Rats; Rats, Wistar; Superoxide Dismutase; Vitamin E | 2023 |